Published in Pharm Biotechnol on January 01, 1995
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38
Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother (2013) 1.10
Working together: interactions between vaccine antigens and adjuvants. Ther Adv Vaccines (2013) 1.00
Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol (2013) 1.00
Disparate adjuvant properties among three formulations of "alum". Vaccine (2012) 0.95
Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides. J Med Chem (2012) 0.90
Mucosal adjuvant properties of the Shigella invasin complex. Infect Immun (2006) 0.85
Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations. J Virol (2014) 0.84
Adjuvants and inactivated polio vaccine: a systematic review. Vaccine (2012) 0.83
InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett (2015) 0.82
Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives. Biomed Res Int (2014) 0.78
A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms. Sci Rep (2015) 0.75
The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst (1993) 1.93
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol (1993) 1.78
Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis (1996) 1.20
Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydr Res (1996) 1.10
Isomerization and formulation stability of the vaccine adjuvant QS-21. J Pharm Sci (1996) 1.08
The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo. J Immunol (1990) 1.02
Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. J Immunol (1994) 0.99
Twenty-four hour emergency pharmaceutical services. Am J Hosp Pharm (1985) 0.89
RhNGF slow unfolding is not due to proline isomerization: possibility of a cystine knot loop-threading mechanism. Protein Sci (1996) 0.87
Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine (1997) 0.85
Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. J Pharm Sci (1998) 0.82
Immunological and formulation design considerations for subunit vaccines. Pharm Biotechnol (1995) 0.82
Evaluation of a cardiopulmonary-resuscitation training manual for pharmacists. Am J Hosp Pharm (1983) 0.80
Diabetic patient compliance as a function of patient counseling. Drug Intell Clin Pharm (1979) 0.80
Concerning 1e- transfer in reduction by dihydronicotinamide: reaction of oxidized flavin and flavin radical with N-benzyl-1,5-dihydronicotinamide. Proc Natl Acad Sci U S A (1982) 0.78
Formulation development and primary degradation pathways for recombinant human nerve growth factor. Anal Chem (1997) 0.78
Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines. AIDS Res Hum Retroviruses (1998) 0.77
Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. J Pharm Sci (1996) 0.77
Development of a single-shot subunit vaccine for HIV-1. AIDS Res Hum Retroviruses (1994) 0.77
Enhanced stability of codeine sulfate: effect of pH, buffer, and temperature on the degradation of codeine in aqueous solution. J Pharm Sci (1986) 0.76
Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J Pharm Sci (1996) 0.75
Evaluation of a method for intravenous phenytoin infusion. Clin Pharm (1983) 0.75
Temperature and pH dependence of fluocinolone acetonide degradation in a topical cream formulation. Pharm Res (1987) 0.75
Stability of alkoxycarbonylamidine prodrugs. Pharm Res (1998) 0.75
Use of the annual report concept for the department of hospital pharmacy services. Hosp Pharm (1988) 0.75
Stability of prostacyclin analogues: an unusual lack of reactivity in acid-catalyzed alkene hydration. Pharm Res (1988) 0.75
Pharmacist participation in a multidisciplinary, community health-education project. Am J Hosp Pharm (1982) 0.75
Quality assurance aspects of purchasing and inventory control. Top Hosp Pharm Manage (1983) 0.75
Tampering with tamperproof containers. Am J Hosp Pharm (1986) 0.75
Aortocaval compression during early pregnancy: are there other causes? Int J Obstet Anesth (2013) 0.75
Pharmaceutical perpetual inventory: a comprehensive approach. Top Hosp Pharm Manage (1988) 0.75
An analysis of 1986 drug procurement practices in hospitals within the United States. Hosp Pharm (1989) 0.75
Labor standard development for a decentralized mobile cart unit dose drug distribution system. Hosp Pharm (1989) 0.75
Justification for a pediatric satellite pharmacy at a tertiary-care institution. Am J Hosp Pharm (1992) 0.75
Using the business plan to propose revenue-generating pharmacy services. Hosp Pharm (1988) 0.75